

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claim 1. (previously presented): A neovascularization inhibitor comprising the following polypeptide (a) or (b) as an active ingredient:

(a) a polypeptide having the amino acid sequence of SEQ ID NO: 1; or

(b) a polypeptide having the amino acid sequence of SEQ ID NO: 2;

wherein each of polypeptides (a) and (b) has at least one hairpin domain and four Kringle domains.

Claim 2. (previously presented): The neovascularization inhibitor according to claim 1, comprising the polypeptide having the amino acid sequence of SEQ ID NO: 2, wherein the polypeptide having the amino acid sequence of SEQ ID NO: 2 has at least one hairpin domain and four Kringle domains.

Claim 3. (canceled).

Claim 4. (previously presented): The neovascularization inhibitor as set forth in claim 1 or 2, wherein said polypeptide is obtainable by elastase digestion of human hepatocyte growth factor harboring a deletion of amino acids 162-166.

Claim 5. (canceled).

Claim 6. (previously presented): A neovascularization inhibitor composition comprising the polypeptide having the amino acid sequence of SEQ ID NO: 2 and a pharmaceutically acceptable carrier.

Claims 7-11. (canceled).

Claim 12. (previously presented): A method of inhibiting neovascularization which comprises administering to a subject in need of such treatment a neovascularization inhibitor composition comprising the following polypeptide (a) or (b) and a pharmaceutically acceptable carrier:

(a) a polypeptide having the amino acid sequence of SEQ ID NO: 1; or

(b) a polypeptide having the amino acid sequence of SEQ ID NO: 2;

wherein each of polypeptides (a) and (b) has at least one hairpin domain and four Kringle domains.

Claim 13. (previously presented): A method of inhibiting neovascularization which comprises administering to a subject in need of such treatment a neovascularization inhibitor

composition comprising the following polypeptide (a) or (b) and a pharmaceutically acceptable carrier:

- (a) a polypeptide having the amino acid sequence of SEQ ID NO: 1; or
- (b) a polypeptide having the amino acid sequence of SEQ ID NO: 2;

wherein each of polypeptides (a) and (b) has at least one hairpin domain and four Kringle domains.

Claim 14. (previously presented): A method for treating a disease associated with abnormal angiopoiesis which comprises administering, to a subject in need of such treatment, a neovascularization inhibitor composition comprising the following polypeptide (a) or (b) and a pharmaceutically acceptable carrier:

- (a) a polypeptide having the amino acid sequence of SEQ ID NO: 1; or
- (b) a polypeptide having the amino acid sequence of SEQ ID NO: 2;

wherein each of polypeptides (a) and (b) has at least one hairpin domain and four Kringle domains.

Claim 15. (canceled).

Claim 16. (withdrawn-currently amended): The method of claim 14 ~~or 15~~, wherein said disease is any disease selected from the group consisting of rheumatoid arthritis, psoriasis, Osler-Webber syndrome, myocardial angiopoiesis, telangiectasia, hemophilic joint, angiogenic

diseases of the eye, angiofibroma, benign tumors, wound granulation, enteric adhesion, Crohn's disease, atherosclerosis, scleroderma and overcicatrizization.

Claims 17-27. (Canceled)

Claim 28. (previously presented): A method for treating a solid cancer and/or cancer metastasis, which comprises administering to a subject in need of such treatment a pharmaceutical composition containing the following polypeptide (a) or (b):

(a) a polypeptide having the amino acid sequence of SEQ ID NO 1; or

(b) a polypeptide having the amino acid sequence of SEQ ID NO: 2;

wherein each of polypeptides (a) and (b) has at least one hairpin domain and four Kringle domains.

Claim 29. (previously presented): A method for treating a solid cancer and/or cancer metastasis, which comprises administering to a subject in need of such treatment a pharmaceutical composition containing the polypeptide having the amino acid sequence of SEQ ID NO: 2.

Claim 30. (previously presented): The method as claimed in Claim 28 or Claim 29, wherein said subject has a lung cancer or mammary cancer.

Claim 31. (previously presented): A method for inhibiting tumor growth or metastasis, which comprises administering to a subject in need of such treatment a pharmaceutical composition containing the following polypeptide (a) or (b):

(a) a polypeptide having the amino acid sequence of SEQ ID NO: 1; or

(b) a polypeptide having the amino acid sequence of SEQ ID NO: 2;

wherein each of polypeptides (a) and (b) has at least one hairpin domain and four Kringle domains.

Claim 32. (currently amended): A method for inhibiting tumor growth ~~or metastasis~~
or metastasis, which comprises administering to a subject in need of such treatment a pharmaceutical composition containing the polypeptide having the amino acid sequence of SEQ ID NO: 2.

Claim 33. (previously presented): The method for inhibiting tumor growth or metastasis as claimed in Claim 31 or Claim 32, wherein the subject has lung cancer or mammary cancer.

Claim 34. (previously presented): A method for treating a disease arising from vascular hyperplasia and/or caused by an excessive or abnormal stimulation of the endothelial cells, which comprises administering to a subject in need of such treatment a pharmaceutical composition containing the following polypeptide (a) or (b):

(a) a polypeptide having the amino acid sequence of SEQ ID NO: 1; or

(b) a polypeptide having the amino acid sequence of SEQ ID NO: 2;

wherein each of polypeptides (a) and (b) has at least one hairpin domain and four Kringle domains.

Claim 35. (previously presented): A method for treating a disease arising from vascular hyperplasia or/and caused by an excessive or abnormal stimulation of the endothelial cells, which comprises administering to a subject in need of such treatment a pharmaceutical composition containing the polypeptide having the amino acid sequence of SEQ ID NO: 2.

Claim 36. (previously presented): The method of Claim 34 or Claim 35, wherein said disease is a disease selected from the group consisting of rheumatoid arthritis, psoriasis, Osler Webber syndrome, myocardial angiopoiesis, telangiectasia, hemophilic joint, angiogenic diseases of the eyes, angiofibroma, benign tumors, hematopoietic malignancies, wound granulation, enteric adhesion, Crohn's disease, atherosclerosis, scleroderma and over cicatrization.

Claim 37. (Withdrawn-previously presented): A method for controlling conception which comprises administering to a subject a pharmaceutical composition comprising the following polypeptide (a) or (b):

(a) a polypeptide having the amino acid sequence of SEQ ID NO: 1; or

AMENDMENT UNDER 37 C.F.R. § 1.114(c)
U.S. Application No.: 09/674,377

Attorney Docket No.: Q61434

(b) a polypeptide having the amino acid sequence of SEQ ID NO: 2;

wherein each of polypeptides (a) and (b) has at least one hairpin domain and four Kringle domains.